What Eradivir does

Eradivir Inc. is a privately held, clinical-stage biotechnology company founded in March 2020 and headquartered in West Lafayette, Indiana, in close affiliation with Purdue University. The company is developing antibody-recruiting small molecule immunotherapies based on its proprietary Bispecific Antigenic immuno-Therapy (BAiT) platform, which engineers molecules that bind to diseased cells and recruit the anti-hapten antibodies present in all humans, activating NK cells, macrophages and the complement cascade to selectively eliminate infected cells. Eradivir was co-founded by Dr. Philip S. Low, a Purdue biochemist with over 45 years of targeted small molecule research and 100+ patents, whose prior venture Endocyte was acquired by Novartis for $2.1B in 2018; Dr. Low passed away on March 4, 2026.

The company's pipeline centers on two candidates. EV25 is the lead molecule for influenza, linking two immunologic hapten "hooks" to a Neuraminidase Targeting Ligand (NTL) that targets a conserved region across all influenza strains; EV25 completed Phase 1/2a trials in 2025 demonstrating safety, tolerability and significant viral load reduction, with a Phase 2b trial planned for the 2026-2027 influenza season in the US and Europe. EV148 was nominated in February 2026 as the development candidate for respiratory syncytial virus (RSV), with preclinical single-dose data showing greater than 99% viral load reduction in both upper and lower respiratory tract when administered up to 96 hours post-infection, and IND-enabling studies underway with clinical entry targeted for 2026. The platform is positioned as adaptable to additional viral infections (HIV, HBV) and oncological indications.

Eradivir is pre-revenue and operates a standard clinical-stage biotech commercialization model: revenue is expected to come from sales of approved therapeutics distributed through pharmacy benefit managers, wholesalers and specialty pharmacies following FDA/EMA approval. The company has raised approximately $20.25M across a $10.25M Series A in September 2024 and a $10M private financing in October 2025, with funding allocated to Phase 2a/2b influenza trials and RSV IND-enabling work. Operations rely on Contract Development and Manufacturing Organizations (CDMOs) for drug substance, drug product and analytical support, and the company conducts trials under ICH GCP guidelines with disclosures posted to ClinicalTrials.gov and EUClinicalTrials.eu.

Name

Eradivir

Legal name

Eradivir Inc.

Website

https://eradivir.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Eradivir is a clinical-stage biotech developing antibody-recruiting small molecule immunotherapies via its BAiT platform, with lead candidate EV25 in Phase 2b planning for influenza and EV148 in IND-enabling studies for RSV, targeting patients with respiratory viral infections.

Ownership category

akta.pro rank

Product category

Antiviral Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Antiviral therapeutics
• Immunotherapy platform
• Small molecule drugs
• Influenza treatment
• Clinical stage biotech

Headquarters

HQ city

West Lafayette

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Revenue will be generated from sales of approved therapeutics (EV25 for influenza, EV148 for RSV) upon successful clinical development and regulatory approval. Typical biotech commercialization model with pricing through pharmacy benefit managers and insurance coverage.
2. Private Financing: Company raised $10 million in private funding round (October 2025) and previously $10.25 million Series A (September 2024) to fund clinical and preclinical trials including Phase 2a influenza study and IND-enabling studies for RSV.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Eradivir is a clinical-stage biotechnology company developing antibody-recruiting small molecule immunotherapies based on its proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform for viral infections. Its pipeline includes EV25 (lead molecule for influenza treatment, completed Phase 2a) and EV148 (development candidate for respiratory syncytial virus (RSV), in IND-enabling studies).

Product overview

Eradivir is a clinical-stage biotechnology company developing antibody-recruiting small molecule immunotherapies based on its proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform. The company's portfolio includes two core therapeutic candidates: EV25 (lead molecule for influenza treatment, completed Phase 2a), and EV148 (development candidate for RSV, in IND-enabling studies). The BAiT platform enables the development of molecules that tether patients' immune cells specifically to diseased cells, facilitating their rapid and selective destruction. The company is also developing variants for other respiratory viruses and non-viral infections.

Differentiator

Problem solved

Functional benefit

Products and services

• EV25

Quantifiable outcome

• EV25 significantly reduces viral loads and influenza symptoms in Phase 2a clinical trial (October 2025)
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• CDMO PartnerscoreImplementation/ SI/ Consulting PartnerCompany works with Contract Development and Manufacturing Organizations (CDMOs) for drug product, drug substance and analytical support to ensure process development and manufacturing for clinical studies.
• Low LabscoreStrategic or Co-development PartnerAffiliated research facility at Purdue University where company research is conducted. U.S. Senator Jim Banks visited the Eradivir headquarters and Low Labs facility alongside NIH Director Jay Bhattacharya.
• EU Clinical Trials RegistryminorOthersCompany posts clinical trial updates to EUClinicalTrials.eu and ClinicalTrials.gov as part of commitment to transparency within the scientific and patient community.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Moderna: Moderna is developing mRNA vaccines for influenza and RSV. Comparable as a clinical-stage/scaling biotech targeting the same viral indications with an immune-based mechanism, though using a different technology platform.
• AbCellera Biologics: AbCellera is an antibody discovery platform that has generated antiviral antibodies including for influenza. Comparable as an immune-based antiviral discovery company with overlapping therapeutic area focus.
• Novavax: Novavax develops nanoparticle vaccines for influenza and RSV. Comparable as a smaller-cap biotech targeting the same viral respiratory indications through immune-engagement approaches.

Broad incumbents

• Pfizer: Pfizer acquired ReViral (an RSV antiviral developer) and markets nirsevimab for RSV prevention through its partnership with AstraZeneca. Represents a large-pharma acquirer and competitor in the RSV therapeutic space relevant to EV148.
• Roche: Roche markets Tamiflu (oseltamivir), the dominant influenza antiviral. Represents the incumbent standard of care that Eradivir's EV25 must outperform to gain meaningful market share.
• Shionogi: Shionogi developed Xocova (ensitrelvir), a COVID-19 antiviral, and has broader antiviral and infectious disease portfolio. Comparable as a major pharma with antiviral drug development and commercialization capabilities.
• Johnson & Johnson: Janssen (J&J) markets Xofluza (baloxavir marboxil), a leading single-dose influenza antiviral. A direct competitive threat to EV25 with established commercial channels and influenza franchise infrastructure.

Direct peers

• Vir Biotechnology: Vir Biotechnology develops antibody-based immunotherapies for serious infectious diseases including influenza and RSV. Directly comparable to Eradivir as a clinical-stage biotech leveraging immune-based mechanisms against viral infections.
• Cidara Therapeutics: Cidara Therapeutics develops antiviral conjugates and immune-recruiting therapeutics (Cloudbreak platform) for viral infections. Highly comparable to Eradivir's BAiT approach of using small molecules to recruit immune effectors against viruses.
• Arcturus Therapeutics: Arcturus Therapeutics develops mRNA-based therapeutics and vaccines, including influenza programs. Comparable as a clinical-stage biotech with a distinct platform approach to antiviral therapeutics targeting similar indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eradivir

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eradivir